of annotated concepts in the ontology.
Ontologies and prior work
In this work, we use the term "ontology" to denote a set of concepts covering all important aspects of a domain (here: drug application) and their semantic relationships. Concepts have names, are described by a human readable definition, and may have synonyms. We use the word "term" to denote a name of a concept in the ontology. Such a term may consist of several words.
For our purposes, ontologies serve several functions:
• They provide a standard vocabulary for annotations of biomedical entities, helping to integrate and to search across data sources of different origins and authors [11] .
• With ontologies, terms and their domain of application could be specified as exact as possible for the representation of medical knowledge in algorithms and knowledge bases and therefore, sensitivity and specificity of algorithms and knowledge bases can be enhanced [12, 13] .
• Ontologies enhance search capabilities because the semantic relationships between concepts implicitly define groups. For instance, the ontology may define that solution, emulsion, and suspension are all specializations of the concept liquid formulation. Searching for liquid formulation will then also return all drugs annotated with any of these three dosage forms.
• These implicitly defined groups also enable the specification of statements about groups of annotated objects. For instance, one may express that patients on anticoagulants should not be given an intramuscular injection of diclofenac.
• Ontologies enable meaningful similarity searches among drugs. For instance, based on the relationships between concepts in an ontology, an algorithm is able to decide that a capsule is more similar to a tablet than a syrup. Such comparisons are, for instance, an essential prerequisite for drug switching. There are several suggestions on how such a similarity should be computed, ranging from simple term equality over exploitation of the hierarchical relationships between concepts [14] to methods that also employ word frequencies (see Popescu et al. [15] for an example using ICD codes) or the number of possible word meanings [16] .
• Finally, ontologies enhance object and concept recognition and the extraction of relationships between objects for information extraction from natural text [17] . They can, for instance, help to automatically extract dosage forms from textual prescriptions.
Prominent examples for ontologies in part covering drugs, drug application, and application units are the Unified Medical Language System (UMLS) [18] , the Logical Observation Identifiers Names and Codes (LOINC) [19] , and the Systematized Nomenclature of Medicine (SNOMED CT) [20] , a health care terminology primarily used to enhance communication and interoperability in electronic health data exchange.
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To our knowledge no such comprehensive model to describe drug applications has been published. Ontologies most closely related are RxNorm, a standardized nomenclature for clinical drugs [21] , and the less established Prodigy Drug Ontology [22] . RxNorm is used to annotate drugs of the US market with attributes such as ingredient, strength, brand name, branded ingredient, or dose form. The Prodigy Drug Ontology considers dosage forms, routes, and application devices. However, the models themselves are not fine-grained enough to support CDS systems with respect to drug application. For instance, the attribute dose form combines route of administration and dosage form, but does not define whether the drug reaches systemic availability and will thus neither support dose adjustment in renal failure nor drug interaction alerts. Thus, present models are less complete and lack a semantic structure to comprehensively support the numerous tasks of a CDS considering drug application (e.g. similarity calculations). Certain aspects of drug application are also described in ABDATA (ABDATA Pharma-Daten-Service, Eschborn, Germany) [23] , which provides detailed information on dosage forms for all drugs marketed in Germany. It distinguishes between presentation form and administration form. However, it does not organize the definitions in a semantic structure and can thus not be used to deduce dependencies or similarities of parameters of drug application relevant for effective and safe use.
In conclusion available ontologies were built for other purposes and thus lacked important aspects with respect to drug application. Instead of refining one of the already existing ontologies with their obvious limitations we therefore decided to build a new model with a strict and convenient schema as a basis of a versatile CDS system. Concurrently we ensured that integration of the terms of our ontology into existing terminologies will be easy to accomplish.
Example drugs
The effectiveness of our model was exemplarily evaluated with a complete annotation of the hospital formulary of the University Hospital of Heidelberg (N=2,450), giving a representative cross-section of all marketed drugs (assuming that about 53% of all described drugs outside a hospital are also found on the hospital fomulary [9] ). Furthermore, four frequently used active ingredients were chosen because they represent prominent published examples of drugs that are known
(1) to cause medication errors because of drug application issues (i.e. amphotericin B) [4, 5] , (2) to trigger over-alerting if drug application characteristics are neglected (i.e. ciprofloxacin) [6] , or 
II. METHODS

Schema development
Previous definitions concerning drug application focused on the dosage form of the drug and its route of administration [21, 22, 24] . These attributes represent an essential part of but do not sufficiently map all aspects of drug application. On the basis of these attributes a first version of our schema was defined. We then identified further attributes that were indispensable for Senger/Seidling drug application ontology page 10 of 37 evaluation of drug prescriptions and within this process added or modified several attributes, such as the availability of drugs (addition), the way in which systemic availability is reached (attribute absorption, addition), or the differentiation between dosage form and route of administration (refinement).
Ontology development
The strategy for identifying concepts followed a computer aided bottom-up approach because the complete (but ambiguous) descriptions of all drug products were available. A manual top-down approach was also applied in a subsequent step to clarify the structure, discard possible redundancies, and extend the structure and vocabulary if concepts were missing.
Schema attributes where interconnected by IS-A relationships as well as ontology concepts.
Another expression was applied through connections describing the schema attribute(s) to which individual concepts belong to. Hence, the hierarchic level of each concept was easily accessible for similarity calculations and the linkage of knowledge of CDS on different levels of detail.
Schema and ontology were constructed and implemented with a tree-like structure in a Relational Database Management System, utilizing interfaces and forms supplied by Microsoft Access and graph visualization tools.
An interdisciplinary team of two pharmacists, two scientists in the area of bio-/medical informatics, and four physicians/medical students screened definitions of drug application published by the authorities. We searched the online available definitions for drug preparations for human use of the US Food and Drug Administration for dosage forms and routes of administration [22, 24] , the European Pharmacopeia (EuAB) [25] , the Standard Terms as they are published by the European Directorate for the Quality of Medicines [26] , German dosage forms as defined by MMI (Medizinische Medien Informations GmbH, Neu-Isenburg, Germany) [27] , and ABDATA (ABDATA Pharma-Daten-Service, Eschborn, Germany) [23] .
In total, 1123 definitions were collected and analyzed. Note that a definition usually consists of multiple words or phrases and often contains values for different attributes of our schema. Therefore, a definition in general cannot be mapped to a single ontology concept, but first needs to be broken into semantic units. These units were then mapped to terms of the ontology, added as synonyms, or used to extend the ontology. For example, the definition "Powder for suspension for injection" is fragmented into powder (referring to basic presentation form), suspension (referring to basic form of administration), and for injection (referring to mode of application).
Annotation of drug products
We used our ontology to annotate all drugs currently available on the German market.
Drugs were annotated in a three-step process ( Figure 1 ). First, basic definitions referring to galenic formulations and route of administration were obtained from MMI. A translation table was compiled, linking one or more concepts to each basic definition. In the second step, drugs were annotated by utilizing the translation table, assigning the concepts of each definition to individual drugs. This process fails whenever the base data do not contain sufficient detail to uniquely identify the corresponding concept of the ontology. Moreover, some aspects of drug application such as information on systemic availability are not covered by traditional definitions of drug application. In a third step we therefore manually completed the annotation for the hospital formulary. Manual curation was supported by an application that provided a userSenger/Seidling drug application ontology page 12 of 37 friendly graphical interface that also guaranteed the logical dependencies specified in the schema. The experts screened the summary of product characteristics (SPCs) for relevant information and, if information was still lacking, consulted manufacturers for detailed information. Annotation guidelines specifying the selection of appropriate terms were defined and six experts were trained accordingly. For quality assurance, every expert annotated a training set of 15 medicinal products with 159 terms on average. Annotations were stored traceable and all differences were discussed considering their possible influence on the ontology but modifications were not necessary. Experts were trained until full accordance with the respective training set of predefined annotations. Successful annotation of the training set was a prerequisite
for working with the real data set. Annotations of the real data were cross-checked by the experts, potential deviations discussed and annotations were adjusted if necessary.
Annotation of drugs with wide and complex ranges of dosage forms
Marketed brands containing diclofenac and lidocaine were used as paradigm drugs to challenge the versatility of the model and to assess the ability to annotate drugs with a wide and complex range of dosage forms or routes of administration.
Comparison of drugs with respect to drug application
Most applications of our ontology will require to reliably identify similar drugs (e.g. for drug switching) or to describe drugs in such detail that information on drug-drug interactions or maximum upper dose limits can be distinguishably and unequivocally linked. We therefore developed a respective method taking the schema and the properties of our ontology into account. Given a query drug, the method returns a list of drugs with the same active ingredients Senger/Seidling drug application ontology page 13 of 37 sorted by similarity to the query drug with respect to drug application. Within the search, the schema is used to determine which values must be compared with each other. Within each attribute, the structure of the ontology attached to this attribute determines the concrete similarity value of annotated drugs.
However, when comparing two drugs certain attributes may need to be treated differently from other attributes. Assume that a solid diclofenac product should be switched to a liquid formulation because of difficulties swallowing (dysphagia). In this situation, it is important to find a drug with a liquid formulation which differs as little as possible from the query drug.
Therefore, some characteristics are mandatory (liquid formulation) whereas others (e.g. packaging) are less important for this application. In the following, we use the term 'soft constraints' to refer to those attributes whose values should only be as similar as possible, and we use 'hard constraints' for conditions on attribute values that must be met.
Computation with soft constraints
To compute soft constraints we adapted the Optimistic Genealogy Measure [28] . Trees represent the taxonomy of concepts belonging to a certain attribute of the schema. As an example, the tree for availability is shown in Figure 2a with individual nodes representing the terms that can be assigned to a drug. Subtrees contain all nodes between the annotated concept and the root of the tree. The subtree of a drug annotated with the concept systemical_enteral is shown in Figure 2b . A drug annotated with systemical_parenteral forms the subtree shown in Figure 2c .
The similarity of two drugs is computed by first determining their similarity for every attribute with respect to the lowest common node of both trees. The overall similarity of the Senger/Seidling drug application ontology page 14 of 37 drugs is computed as the average over the similarities of all attributes. Weights for each attribute allow specific attributes to have a greater (or smaller) influence on the similarity of drugs (e.g.
systemic/topic availability may be more relevant in drug switching than the packaging of a drug).
For the purpose of this study we always set these weights to 1. This similarity measure is asymmetric, i.e. the similarity of drug 1 with drug 2 usually is not the same as the similarity of drug 2 with drug 1. This enables meaningful comparisons of drugs annotated with well defined concepts to those annotated only approximately. For instance, the similarity score of a drug annotated with systemical_parenteral ( Figure 2b ) and one annotated with systemical ( Figure 2d ) will be 0.5, while the reverse comparison will result in a similarity of 1.
Computation with hard constraints
Hard constraints are included in our calculations by a function resulting in 1 if all such criteria are matched and 0 in all other cases. The result of calling this function is multiplied with the similarity value to compute the overall result. Accordingly, the overall similarity of two drugs is 0 if any hard criterion is missing.
Similarity searches with annotated drugs
To evaluate functionality and effectiveness of the ontology, the annotations, and the similarity function we conducted similarity searches. We used marketed brands of ciprofloxacin and amphotericin B as paradigm drugs. We applied searches using only soft constraints and subsequently narrowed down the list by adding hard search constraints.
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Lists with drug products containing ciprofloxacin and amphotericin B were given to three pharmacists performing a manual similarity ranking with respect to soft constraints. Notice of Table I was given to the pharmacists as similarity criteria. Agreement of the results of automatic ranking and expert ranking was measured using Cohen's weighted kappa coefficient, comparing each expert ranking with the automatic ranking.
III. RESULTS
Our model comprises:
• a schema specifying all relevant attributes of drug application,
• a list of all concepts that can be assigned to the attributes of the schema,
• the semantic relationships between concepts, and
• the description of concrete drug products with the most specific concepts of our ontology for all relevant attributes.
Because the set of attributes describing drug applications has an internal structure, the schema also specifies groups of related attributes. The interplay between schema, ontology, and annotations is depicted in Figure 3 .
Schema description
The schema contains 22 attributes and their descriptions (Table I) which are organized in a hierarchical manner (Figure 1 ). Four main attributes are connected to a general node drug application, whose use is purely technical (as a point of entry for structure traversal). They represent the following information:
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• Pharmaceutical form combines the presentation form (type of presentation form, basic form of presentation, presentation form), i.e. the form in which the drug is stored, the administration form (type of administration form, basic form of administration, administration form), i.e. the form in which the drug is finally administered, the drug release, and the dosage unit.
• drug administration pools the site of administration, defined as "organ" where the drug is supposed to be administered, with the route of administration and the mode of administration.
• Absorption defines whether and how a drug reaches systemic availability.
• Packaging specifies the container and potential administration devices in the packaging.
For each main attribute sub-attributes are defined -e.g. the type of presentation form is one aspect of the pharmaceutical form. The concrete values of the attributes often imply logical constraints on the values that child nodes may take (not shown graphically).
For instance, the route of administration imposes restrictions on the site of administration (e.g. if administration site takes the value use in the vascular system, the value intraocular is not an option for the route of administration).
Ontology description the occurrence of undesirable effects of intramuscular injections if anticoagulants have been
given previously -while intravenous injections are adequate [32] ) or substantially different dose requirements of high first-pass compounds if they are given orally as compared to parenteral routes of administration.
To challenge the model we first used an automatic annotation approach and could successfully annotate all available drug products at least approximately. The local hospital formulary as a representative subset of all available drug products was successfully annotated by experts as confirmed by an optimal inter-rater agreement. However, several terms were missing in the first annotation, leading to a less detailed while still correct and useful annotation. The successful annotation of diclofenac and lidocaine products proves the ability of the model to describe drugs with numerous or very complex dosage forms and largely differing administration modes and routes. Thus, we assume that each aspect of drug application for all available drug products could be represented by our model. Table II . However, the inverse comparison would result in a similarity score of 1.0. We believe that this behavior appropriately reflects clinical practice, where specific information usually will be preferred over only approximately described drugs.
The ranking, however, could be further improved by applying weights to the similarity measure.
For instance, it is often advisable to give a greater weight to the attribute administration form and a lower weight to need for preparation or presentation form. Using such a schema for the examples shown previously, the syrup in Table II and the suspension in   Table III would be ranked as more similar to an aqueous solution for infusion than tablets (which are rated higher in the similarity calculations). Clearly, the optimal setting of the different weights depends on the requirements of a specific application. A machine-learning approach with comprehensive training sets related to practice and classified by physicians and pharmacists would be a suitable approach.
Ontologies like RxNorm or the Prodigy Drug Ontology have been developed with the purpose to generally address all medication-related aspects. Thus, while their range is very administration for a medicinal product (e.g. intrathecal administration of vincristine) an alert may be issued.
• Third, also the specificity of many alerts of CDS systems can be substantially enhanced if drug application characteristics are considered. As an example, drug-drug interaction alerts are usually only relevant if the drugs are systemically available and do not occur if either drug's availability is topical. The quality of alerts (e.g. the severity) can be adjusted based on the detailed description of drug application (e.g. major interaction if intravenous β-adrenoceptor antagonists are co-administered with intravenously administered calcium channel blockers compared to an only moderate interaction with oral verapamil).
The model has been established and integrated into the CDS system at the University Hospital of Heidelberg for 1½ years and confirmed its quality and performance in several knowledge base fields including drug-drug interactions. While we believe in the advantages of the model, its benefits have to be proven in a prospective study.
During development and curation of the knowledge bases, scientists give permanent feedback for evaluation and extension of the model. The model is updated every second week with newly available market data. Provision of access to the model for data suppliers and future research projects is planned for the near future.
The current model also has limitations. For instance, we did not include the dosage of medicinal products while other systems, including RxNorm, do model drug dosage. However, drug dosage is rather a link to other medicinal ontologies because drug dosage does not only depend on drug application characteristics but also on the indication of the drug and the patient's individual condition (e.g. kidney function), and co-medication. Properly reflecting these Senger/Seidling drug application ontology page 24 of 37 dependencies therefore requires knowledge of the patient's co-morbidities i.e. links to ICD-10 codes and lab values. Moreover, divisibility of tablets was studied previously [33] and can be attached to the model for all drugs with basic form of administration=tablet.
Only drugs marketed in Germany were annotated, which is one of the largest drug markets of the world. However, annotation can be easily extended to other drugs if the respective information on drug application characteristics is extracted from the label. Finally, annotation of medicinal products requires a frequent update process to ensure high quality and current data. With the two-weekly update, a screening of the SPCs that have been updated by the manufacturer during the preceding two weeks is necessary. Obviously such an update process would be facilitated if the regulatory authorities would ask for such information as a prerequisite for marketing authorization and if it would thus be provided in structured format by the pharmaceutical manufacturer (e.g. as a structured electronic SPC).
V. CONCLUSION
The presented model closes a gap in current CDS systems used in pharmacotherapy by offering a comprehensive and detailed characterization of drug application, which is a prerequisite for highly-specific alerts and drug switching. Tables   Table I Definition of schema attributes. For illustration, the respective ontology terms are shown for an effervescent tablet with systemic availability.
Schema attribute Description
Drug application
General node, point of entry for structure traversal of the schema, the ontology, and the drug products using the example of the metaconcepts "pharmaceutical form". The formal definition of the schema attributes, the inter-schema relationships, and relationships of the concepts allows CDS to link knowledge explicitly to different levels of detail.
